Felodipine Tablet, Film Coated
Product Images NDC 72162-1743

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Felodipine (NDC 72162-1743). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (1 Formula)

Image Description (1 Formula)
FDA Label Image

Label (Lbl721621743)

Label (Lbl721621743)
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
Percent of Patients with Adverse Events in Controlled Trials of Felodipine Extended-Release Tablets: - Body System: - Peripheral Edema: 33 (0) patients on placebo, 2 (0) patients on 25mg, 88 (22) patients on 5mg, and 174 (25) patients on 10mg experienced this adverse event. - Asthenia: 33 (0) patients on placebo, 39 (0) patients on 25mg, 0.33 (0) patients on 5mg, and 22 (0) patients on 10mg experienced this adverse event. - Warm Sensation: 0 (0) patients on placebo, 0 (0) patients on 25mg, 9 (2) patients on 5mg, and 15 (0) patients on 10mg experienced this adverse event. - Cardiovascular: - Palpitation: 24 (0) patients on placebo, 4 (0) patients on 25mg, 14 (3) patients on 5mg, and 25 (5) patients on 10mg experienced this adverse event. - Digestive: - Nausea: 15 (9) patients on placebo, 12 (0) patients on 25mg, 17 (3) patients on 5mg, and 1 (7) patients on 10mg experienced this adverse event. - Dyspepsia: 12 (0) patients on placebo, 39 (0) patients on 25mg, 7 (0) patients on 5mg, and 5 (0) patients on 10mg experienced this adverse event. - Constipation: 9 (0) patients on placebo, 12 (0) patients on 25mg, 3 (0) patients on 5mg, and 15 (0.2) patients on 10mg experienced this adverse event. - Nervous: - Headache: 102 (9) patients on placebo, 106 (4) patients on 25mg, 11 (17) patients on 5mg, and 147 (2) patients on 10mg experienced this adverse event. - Dizziness: 27 (3) patients on placebo, 27 (0) patients on 25mg, 36 (5) patients on 5mg, and 37 (5) patients on 10mg experienced this adverse event. - Paresthesia: 15 (3) patients on placebo, 16 (0) patients on 25mg, 12 (0) patients on 5mg, and 12002 patients on 10mg experienced this adverse event. - Respiratory: - Upper Respiratory Infection: 1.8 (0) patients on placebo, 39 (0) patients on 25mg, 19 (0) patients on 5mg, and 7 (0) patients on 10mg experienced this adverse event. - Cough: 0.3 (0) patients on placebo, 8 (0) patients on 25mg, 12 (0) patients on 5mg, and 17 (0) patients on 10mg experienced this adverse event. - Rhinorthea: 0 (0) patients on placebo, 16 (0) patients on 25mg, 2 (0) patients on 5mg, and 2 (0) patients on 10mg experienced this adverse event. - Sneezing: 0 (0) patients on placebo, 16 (0) patients on 25mg, 0 (0) patients on 5mg, and 0 (0) patients on 10mg experienced this adverse event. - Skin: - Rash: 0 (0) patients on placebo, 2 (0) patients on 25mg, 2 (0) patients on 5mg, and 2 (0) patients on 10mg experienced this adverse event. - Flushing: 0.9 (0.3) patients on placebo, 39 (0) patients on 25mg, 53 (7) patients on 5mg, and 69 (1.2) patients on 10mg experienced this adverse event. Please note that the data includes patients on different doses of felodipine extended-release tablets and the discontinuations were shown in parentheses.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.